Regulatory Approval of CAR‐T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan

Documenti analoghi

• Characteristics of Drugs from Non‐Global Companies for Hematologic Malignancies and Impact on Global Regulatory Approval
  di: Kensuke Matsuda, et al.
  Pubblicazione: (2024)
• Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
  di: Mohamed A. Kamal, et al.
  Pubblicazione: (2024)
• Regulatory Issues of Platform Trials: Learnings from EU‐PEARL
  di: Quynh Lan Nguyen, et al.
  Pubblicazione: (2024)
• Off‐Label Use of Mycophenolate: Can Real‐World Evidence Fetch Regulatory Approval for Lupus Nephritis and Other Indications?
  di: Nisha Sharma, et al.
  Pubblicazione: (2024)
• Clinical Benefit, Trials, and Regulatory Approval of Oncology Indications Under Multiple Expedited Programs for Drug Marketing in China, 2018–2024
  di: Jie Zhang, et al.
  Pubblicazione: (2025)